Taiwan News10h
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...
Applied Clinical Trials Online16h
Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS
FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...
Medscape1d
Urticaria, Angioedema, and Anaphylaxis Highlights From AAAAI
The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...
Targeted Oncology1d
Jurczak on BTK Inhibitors and the Future of B-Cell Lymphoma Therapy
Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...
Pulmonology Advisor1d
Remibrutinib Beneficial for Urticaria After H1-Antihistamine Treatment
Remibrutinib results in significant improvement in composite measure of itching and hives after second-generation H1-antihistamine treatment.
Medscape1d
Hematologist Dives Deep on MPN Research, Explains It Clearly
Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...
Targeted Oncology3d
The Evolution of BTK Inhibitors in B-Cell Lymphoma
Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.
The American Journal of Managed Care5d
In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib
A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...
International Harrington Prize Awarded to Dr. Owen Witte
Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President's Chair in Developmental Immunology, David Geffen School of Medicine ...